The invention belongs to the technical field of STM2457 research, and particularly relates to novel application of STM2457. The invention relates to application of STM2457 in preparation of medicines for preventing and treating tumor diseases. In some embodiments,
lung cancer is non-
small cell lung cancer; and the action concentration of the STM2457 is 5 [mu]M. The invention also discloses application of the STM2457 in preparation of at least one selected from the group consisting of an
NSCLC cell retardation proliferation preparation, an
NSCLC cell transfer inhibitor and an
NSCLC cell apoptosis promoting preparation. The invention also relates to application of the STM2457 in preparation of a CYP19A1 expression inhibitor. The expression of the CYP19A1 is a CYP19A1
protein; and the action concentration of the STM2457 is 5 [mu]M. The invention further relates to application of the STM2457 in preparation of an
estrogen signal channel inhibitor. The
estrogen signal channel is an NSCLC associated
estrogen signal channel. The invention also relates to application of the STM2457 in preparation of an METTL3 activity inhibitor. The invention develops a novel therapeutic
drug for NSCLC, provides a novel therapeutic scheme, and is expected to inhibit the progress of NSCLC on the basis of overcoming
tumor heterogeneity; and an effective activity inhibitor is provided for METTL3, and the change rule of
molecular targets and the potential mechanism of
tumor inhibition are clarified. Meanwhile, other novel application of the STM2457 is researched.